Shareholders That Lost Money on Medifast, Inc. (MED) Should Contact Levi & Korsinsky About Securities Fraud Investigation - MED
NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medifast, Inc. ("Medifast") (NYSE:MED) concerning possible violations of federal securities laws. Medifast reported its quarterly earnings on April 29, 2024.
The Schall Law Firm Is Opening An Investigation Into Medifast, Inc. And Encourages Investor Participation
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Announces An Investigation Into Claims Against Medifast, Inc. And Invites Investor Participation
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Medifast (MED) Tumbles 25% in 3 Months: Should You Buy Now?
Medifast (MED) is encountering difficulties in attracting customers due to a reduction in the number of active OPTAVIA Coaches and diminished productivity per Coach.
Medifast (MED) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
Medifast's (MED) Q2 results highlight the challenges of poor customer acquisition. However, the company is focusing strategically on medically supported weight loss, indicating potential for growth.
Medifast, Inc. (MED) Q2 2024 Earnings Call Transcript
Medifast, Inc. (NYSE:MED ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Steven Zenker - Vice President, Investor Relations Dan Chard - Chairman and Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants James Salera - Stephens Linda Bolton-Weiser - D.A. Davidson David Larsen - BTIG Operator And welcome to the Medifast Second Quarter 2024 Earnings Conference Call.
Medifast (MED) Q2 Earnings and Revenues Beat Estimates
Medifast (MED) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $2.77 per share a year ago.
Medifast (MED) Q2 Earnings in the Cards: Factors to Watch
Medifast's (MED) Q2 results are likely to reflect customer acquisition challenges stemming from the growth of GLP-1 medications in markets.
Time to Unload: 3 Stocks in Deep Trouble to Sell Now
The end of the pandemic served as a springboard for the economy, launching us into a new bull market. I can't blame people for being optimistic after seeing the meteoric rise of several big-name stocks.
Medifast (MED) Lags Industry in 3 Months: How to Play Ahead?
While Medifast (MED) is implementing a series of measures to propel its growth trajectory, the challenges related to customer acquisition and high marketing expenses keep it in a tight spot.
Investor Participation Is Invited As The Schall Law Firm Announces An Investigation Into Claims Against Medifast, Inc.
LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Medifast (MED) Tumbles More Than 40% in 3 Months: Here's Why
Medifast (MED) battles persistent customer acquisition challenges aggravated by macroeconomic factors and the rising popularity of weight loss medications.
